Drug intelligence / Profile preview

Xi Bi Powder

Development stage: Preclinical
Lead developer: Chongqing Kewei joint grant
Administration: Oral

Overview

Xi Bi Powder is an oral preparation, likely a Traditional Chinese Medicine (TCM) compound, indicated for the treatment of knee osteoarthritis. It is administered according to traditional Chinese medicine diagnostic principles, with potential adjustments to its composition based on individual patient needs. Clinical studies suggest that it may improve clinical symptoms, reduce pain, and exert its therapeutic effects by regulating immune-related proteins and inhibiting inflammatory responses, potentially contributing to the alleviation of cartilage degeneration.

Beyond the preview

Go deeper on Xi Bi Powder.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xi Bi Powder.

Explore the full profile